Newsroom

February 11, 2021

Non-Regulatory

Guard Therapeutics patent granted in Australia

Guard Therapeutics has obtained patent protection in Australia for their biological investigational drug ROSgard, both as product and for its use in medicine.

In addition to the patent grant in Australia (patent no. 2017235608), Guard Therapeutics has also received a Notice of Allowance in the US. Patent protection of ROSgard is currently under review in several other jurisdictions, including e.g. Europe, Japan, China, and Canada.

For further information, please contact:

Tobias Agervald, CEO
Telephone: +46 46 286 50 30
E-mail: info@guardtherapeutics.com 

About Guard Therapeutics

Guard Therapeutics’ investigational drug ROSgard has been documented in several preclinical studies to protect against cell and organ damage, including acute kidney damage, by counteracting oxidative stress and supporting regenerative processes. Guard Therapeutics is listed on Nasdaq First North Growth Market Stockholm.

Certified Adviser is Svensk Kapitalmarknadsgranskning AB, tel. +46 11 32 30 732, ca@skmg.se.

Attachments

Guard Therapeutics patent granted in Australia

Guard Therapeutics patent granted in Australia